Tropical Doctor > Volume 39, Number 4 > Pp. 207-210

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Keramat, F. Articles by Zeraati, F. PubMed PubMed Citation Social Bookmarking                      What's this?

Articles

A comparative trial of three therapeutic regimens: ciprofloxacin-rifampin, ciprofloxacin-doxycycline and doxycycline-rifampin in the treatment of brucellosis

Fariba Keramat ^*   Mitra Ranjbar    Mojgan Mamani ^*   Seyyed Hamid Hashemi ^*    Fatemeh Zeraati 

^* Department of Infectious Diseases; Department of Pharmacology, Hamedan University of Medical Sciences, Hamedan; Department of Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran

Correspondence to: Dr Seyyed Hamid Hashemi, Division of Infectious Diseases, Mirzadeh-Eshghi Street, Sina Hospital, Hamedan, Iran Email: shahashemi{at}yahoo.com

This study was designed to compare the efficacy of ciprofloxacin plus rifampin (CR) and ciprofloxacin plus doxycycline (CD) versus doxycycline plus rifampin (DR) in the treatment of brucellosis. A total of 178 patients with brucellosis who were referred to the Sina Hospital, Hamedan, Iran, were included. The responses to therapy were observed in 166 cases (93.7%) – 59 were in the DR group, 59 in the CR group and 48 in the CD group. No significant differences in the therapeutic responses were observed (P = 0.09). Relapse was observed in 11.7% (DR 7.7%, CR 8.3% and CD 17.5%) after a six-month follow-up. No significant differences were also observed in relapse rates among the three groups (P = 0.35). We concluded that DR is still the first choice regimen and CR or CD may be used as alternatives for treatment of brucellosis in adults.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?